Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Zoledronic acid and atrial fibrillation in cancer patients.

Arslan C, Aksoy S, Dizdar O, Dede DS, Harputluoglu H, Altundag K.

Support Care Cancer. 2011 Mar;19(3):425-30. doi: 10.1007/s00520-010-0868-z. Epub 2010 Apr 1.

PMID:
20358384
2.

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.

Woodis CB.

Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27.

PMID:
18505912
3.

[Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].

Dalle Carbonare L, Bertoldo F, Lo Cascio V.

Reumatismo. 2009 Jan-Mar;61(1):54-64. Italian.

4.

[Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].

Geusens PP, Lems WF.

Ned Tijdschr Geneeskd. 2007 Jun 30;151(26):1445-8. Dutch.

PMID:
17633971
5.

Yearly zoledronic acid in postmenopausal osteoporosis.

Poole KE, Kaptoge S, Reeve J.

N Engl J Med. 2007 Aug 16;357(7):711-2; author reply 714-5. No abstract available.

PMID:
17703530
6.

Zoledronic acid: a review of its use in the treatment of osteoporosis.

Deeks ED, Perry CM.

Drugs Aging. 2008;25(11):963-86. doi: 10.2165/0002512-200825110-00007. Review.

PMID:
18947264
7.

Yearly zoledronic acid in postmenopausal osteoporosis.

Karam R, Camm J, McClung M.

N Engl J Med. 2007 Aug 16;357(7):712-3; author reply 714-5. No abstract available.

PMID:
17703529
8.

Yearly zoledronic acid in postmenopausal osteoporosis.

de Nijs RN, Westgeest AA.

N Engl J Med. 2007 Aug 16;357(7):711; author reply 714-5. No abstract available.

9.

Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.

John Camm A.

Clin Ther. 2010 Mar;32(3):426-36. doi: 10.1016/j.clinthera.2010.03.014. Review.

PMID:
20399982
10.

Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid.

Shah SR, Jean GW, Keisner SV, Ussery SM, Dowell JE.

Support Care Cancer. 2012 Jan;20(1):87-93. doi: 10.1007/s00520-010-1067-7. Epub 2011 Jan 1.

PMID:
21197550
11.

Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.

[No authors listed]

Prescrire Int. 2008 Aug;17(96):143.

PMID:
19480098
12.

[Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].

Ringe JD.

MMW Fortschr Med. 2009 Mar 5;151(10):7. German. No abstract available.

PMID:
19472655
13.
14.

[Osteoporosis and bisphosphonates].

Zuber MA.

Z Rheumatol. 2007 Dec;66(8):713-5. German. No abstract available.

PMID:
17955251
15.

Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.

McKeage K, Plosker GL.

Pharmacoeconomics. 2008;26(3):251-68. Review.

PMID:
18282018
16.

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.

Hwang JS, Chin LS, Chen JF, Yang TS, Chen PQ, Tsai KS, Leung PC.

J Bone Miner Metab. 2011 May;29(3):328-33. doi: 10.1007/s00774-010-0223-y. Epub 2010 Oct 5.

PMID:
20922438
17.
18.

Intravenous zoledronic acid for the treatment of osteoporosis.

Lewiecki EM.

Curr Osteoporos Rep. 2008 Mar;6(1):17-23. Review.

PMID:
18430396
19.

Atrial fibrillation following intravenous zolendronic acid for osteoporosis.

Konsta M, Bournia VK, Dania V, Iliopoulos A.

J Clin Rheumatol. 2014 Jun;20(4):239-40. doi: 10.1097/RHU.0000000000000114. No abstract available.

PMID:
24847757
20.

Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.

Diel IJ, Weide R, Köppler H, Antràs L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.

Support Care Cancer. 2009 Jun;17(6):719-25. doi: 10.1007/s00520-008-0553-7. Epub 2008 Dec 17.

PMID:
19089462
Items per page

Supplemental Content

Write to the Help Desk